General pharmacological profile of the novel muscarinic receptor agonist SNI-2011, a drug for xerostomia in Sjögren's syndrome. 4th communication: Effects on gastrointestinal, urinary and reproductive systems and other effects

Arzneimittel-Forschung/Drug Research

Volumn 52, Issue 4, 2002, Pages 225-232

  Arisawa, Hirohiko ^a   Fukui, Kenji ^a   Imai, Eiichi ^a   Fujise, Nobuaki ^a   Masunaga, Hiroaki ^a  

^a SNOW BRAND MILK PRODUCTS CO LTD   (Japan)

Author keywords

CAS 153504 70 2; Cevimeline; Muscarinic agonist; Sj gren's syndrome; SNI 2011, general pharmacology

Indexed keywords

CEVIMELINE; CHLORIDE ION; ELECTROLYTE; MUSCARINIC RECEPTOR BLOCKING AGENT; SNI 2011; SODIUM ION; WATER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLADDER; BLOOD CLOTTING; BLOOD VESSEL PERMEABILITY; CONTROLLED STUDY; DOG; EDEMA; FEMALE; GASTROINTESTINAL TRACT; GENITAL SYSTEM; GUINEA PIG; HEMOLYSIS; INTESTINE ABSORPTION; MALE; METABOLISM; MOUSE; NONHUMAN; RABBIT; RAT; SJOEGREN SYNDROME; STOMACH SECRETION; STOMACH ULCER; URINARY TRACT; UTERUS; XEROSTOMIA;

EID: 0036231635     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1299885     Document Type: Article

References (13)

1. Sialogogic activities of SNI-2011 compared with those of pilocarpine and McN-A-343 in rat salivary glands: Identification of a potential therapeutic agent for treatment of Sjögren's syndrome
2. (±)-cis-2-methylspiro[1,3-oxathiolane-5,3′-quinuclidine] hydrochloride hemihydrate (SNI-2011, cevimeline hydrochloride) induces saliva and tear secretions in rats and mice: The role of muscarinic acetylcholine receptors
3. Long-lasting salivation by a novel muscarinic agonist SNI-2011 in rats and dogs
4. Studies on antitussives. II. Opium alkaloid and their N-oxides
5. A simple method for the uniform production of gastric ulceration in the rat
6. The effects of drugs on the production and recovery processes of the stress ulcer
7. Carrageenin-induced edema in hind paw of the rat as an assey for antiinflammatory drugs
8. The use of changes in capillary permeability in mice to distinguish between narcotic and nonnarcotic analgesics
9. General pharmacological profile of the novel muscarinic receptor agonist SNI-2011, a drug for xerostomia in Sjögren's syndrome. 1st communication: Effects on general behavior and central nervous system
10. General pharmacological profile of the novel muscarinic receptor agonist SNI-2011, a drug for xerostomia in Sjögren's syndrome. 2nd communication: Effects on somatic nervous system and on autonomic nervous system and smooth muscle
11. General pharmacological profile of the novel muscarinic receptor agonist SNI-2011, a drug for xerostomia in Sjögren's syndrome. 3rd communication: Effects on respiratory and cardiovascular systems